| abstract |
REFERS TO A STABLE ORAL DOSAGE FORM FOR ANTAGONIST AGENTS OF PROTON PUMPS (APAs), BEING SELECTED THE COMPOUNDS: AU-461, 7R, 8R, 9R) -2,3-DIMETHYL-8-HYDROXY- 7- (2-METHOXYETOXY) -9-PHENYL-7,8,9,10-TETRAHYDROIMIDAZO [1,2-h] [1,7] NAPHTHYRIDINE (INN SORAPRAZAN), DBM-819, KR-60436, T-330 , YH-1885, YJA-20379-8 AND 2,3-DIMETHYL-8- (2-ETHYL-6-METHYLBENZYLAMINE) IMIDAZOL [1,2-a] PYRIDINE-6-CARBOXAMIDE, IN WHICH THIS AGENT IS STABILIZED BY MEANS AN EXCIPIENT OF BASIC CHARACTER SUCH AS SODIUM CARBONATE, CALCIUM CARBONATE, MAGNESIUM CARBONATE, MAGNESIUM OXIDE, MAGNESIUM HYDROXIDE, AMONG OTHERS, THOSE PRESENT IN FINALLY DIVIDED FORM AND MIXED IN A BACKGROUND OF THE AGGENDED FORM DOSAGE THAT DISINTEGRATES RAPIDLY WITH AN IMMEDIATE RELEASE OF THE ACTIVE INGREDIENT, ALSO PRESENTS AT LEAST ONE FILLING MATERIAL AND ONE DISINTEGRATING AGENT, AND ONE OR MORE ADDITIONAL EXCIPENTS SUCH AS LUBRICANTS, FLAVORS, COLORS FLAVORS AND SURFACE ACTIVE SUBSTANCES. THE FORM OF ORAL DOSAGE IS SELECTED AMONG TABLETS, COATED TABLETS, GRANULES, MICROTABLETS IN CAPSULES AND GRANULES IN CAPSULES |